日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

FDA批准摘要:Alpelisib用于治疗PIK3CA相关过度生长谱

Singh, Sonia; Bradford, Diana; Li, Xiaoxue; Mishra-Kalyani, Pallavi S; Shen, Yuan-Li; Wang, Lingshan; Zhao, Hong; Xiong, Ye; Liu, Jiang; Charlab, Rosane; Kraft, Jeffrey; Khasar, Sachia; Miller, Claudia P; Rivera, Donna R; Kluetz, Paul G; Pazdur, Richard; Beaver, Julia A; Singh, Harpreet; Donoghue, Martha

Evaluation of somatic copy number variation detection by NGS technologies and bioinformatics tools on a hyper-diploid cancer genome

利用NGS技术和生物信息学工具评估超二倍体癌症基因组的体细胞拷贝数变异检测

Masood, Daniall; Ren, Luyao; Nguyen, Cu; Brundu, Francesco G; Zheng, Lily; Zhao, Yongmei; Jaeger, Erich; Li, Yong; Cha, Seong Won; Halpern, Aaron; Truong, Sean; Virata, Michael; Yan, Chunhua; Chen, Qingrong; Pang, Andy; Alberto, Reyes; Xiao, Chunlin; Yang, Zhaowei; Chen, Wanqiu; Wang, Charles; Cross, Frank Jr; Catreux, Severine; Shi, Leming; Beaver, Julia A; Xiao, Wenming; Meerzaman, Daoud M

FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations

FDA批准摘要:fam-trastuzumab deruxtecan-nxki 用于治疗具有激活 HER2 突变的不可切除或转移性非小细胞肺癌

Mehta, Gautam U; Vellanki, Paz J; Ren, Yi; Amatya, Anup K; Mishra-Kalyani, Pallavi S; Pan, Lili; Zirkelbach, Jeanne F; Pan, Yuzhuo; Liu, Jiang; Aungst, Stephanie L; Miller, Claudia P; Shah, Mirat; Rahman, Nam Atiqur; Theoret, Marc; Kluetz, Paul; Pazdur, Richard; Beaver, Julia A; Singh, Harpreet

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials

PD-L1水平升高对非小细胞肺癌患者PD-1/PD-L1抑制剂治疗效果的影响:11项前瞻性临床试验的汇总分析

Vallejo, Jonathon; Singh, Harpreet; Larkins, Erin; Drezner, Nicole; Ricciuti, Biagio; Mishra-Kalyani, Pallavi; Tang, Shenghui; Beaver, Julia A; Awad, Mark M

US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer

美国食品药品监督管理局批准摘要:纳武利尤单抗联合铂类双药化疗用于可切除非小细胞肺癌患者的新辅助治疗

Akinboro, Oladimeji; Drezner, Nicole; Amatya, Anup; Runyan, Jin; Fourie-Zirkelbach, Jeanne; Zhao, Miao; Bi, Youwei; Korsah, Kwadwo; Mixter, Bronwyn; Tang, Shenghui; Larkins, Erin; Pazdur, Richard; Beaver, Julia A; Singh, Harpreet

Addressing Barriers to Clinical Trial Participation for Transgender People With Cancer to Improve Access and Generate Data

消除跨性别癌症患者参与临床试验的障碍,以改善其获得试验的机会并生成数据

Alpert, Ash B; Brewer, Jamie Renee; Adams, Spencer; Rivers, Lexis; Orta, Sunshine; Blosnich, John R; Miedlich, Susanne; Kamen, Charles; Dizon, Don S; Pazdur, Richard; Beaver, Julia A; Fashoyin-Aje, Lola

Regulatory implications of ctDNA in immuno-oncology for solid tumors

ctDNA在实体瘤免疫肿瘤学中的调控意义

Vellanki, Paz J; Ghosh, Soma; Pathak, Anand; Fusco, Michael J; Bloomquist, Erik W; Tang, Shenghui; Singh, Harpreet; Philip, Reena; Pazdur, Richard; Beaver, Julia A

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

FDA批准摘要:Mobocertinib用于治疗EGFR 20号外显子插入突变的转移性非小细胞肺癌

Duke, Elizabeth S; Stapleford, Liza; Drezner, Nicole; Amatya, Anup K; Mishra-Kalyani, Pallavi S; Shen, Yuan-Li; Maxfield, Kimberly; Zirkelbach, Jeanne Fourie; Bi, Youwei; Liu, Jiang; Zhang, Xinyuan; Wang, Hezhen; Yang, Yuching; Zheng, Nan; Reece, Kelie; Wearne, Emily; Glen, Jacqueline J; Ojofeitimi, Idara; Scepura, Barbara; Nair, Abhilasha; Bikkavilli, Rama Kamesh; Ghosh, Soma; Philip, Reena; Pazdur, Richard; Beaver, Julia A; Singh, Harpreet; Donoghue, Martha

FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

FDA批准摘要:阿特珠单抗作为II期至IIIA期非小细胞肺癌手术切除和铂类化疗后的辅助治疗

Mathieu, Luckson N; Larkins, Erin; Sinha, Arup K; Mishra-Kalyani, Pallavi S; Jafri, Samina; Kalavar, Shyam; Ghosh, Soma; Goldberg, Kirsten B; Pazdur, Richard; Beaver, Julia A; Singh, Harpreet

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

FDA批准摘要:Amivantamab用于治疗携带EGFR 20号外显子插入突变的非小细胞肺癌患者

Chon, Katie; Larkins, Erin; Chatterjee, Somak; Mishra-Kalyani, Pallavi S; Aungst, Stephanie; Wearne, Emily; Subramaniam, Sriram; Li, Yangbing; Liu, Jiang; Sun, Jielin; Charlab, Rosane; Zhao, Hong; Saritas-Yildirim, Banu; Bikkavilli, Rama Kamesh; Ghosh, Soma; Philip, Reena; Beaver, Julia A; Singh, Harpreet